Skip to main content

Table 1 Clinical features of PD patients and healthy controls

From: Increased Tc17 cell levels and imbalance of naïve/effector immune response in Parkinson’s disease patients in a two-year follow-up: a case control study

  Ctrl-0 yr PD-0 yr Ctrl-1 yr PD-1 yr Ctrl-2 yr PD-2 yr Ctrl-0 yr vs PD-0 yr
P-value
Ctrl-1 yr vs PD-1 yr
P-value
Ctrl-2 yr vs PD-2 yr
P-value
N 22 32 19 22 12 10
Age (years)¢ 55.59 ± 10.22 60.81 ± 10.23 54.37 ± 8.01 61.95 ± 11.95 56.42 ± 10.35 57.70 ± 11.04 0.072 0.027* 0.662
Male: female ratio^ 54:46 56:44 58:42 67:33 58:42 50:50
Body mass index¢ 26.85 ± 3.89 27.52 ± 4.54 27.13 ± 3.62 27.14 ± 4.26 27.17 ± 4.38 26.87 ± 5.68 0.549 0.952 0.974
Symptom duration (years) ¢ NA 2 ± 1.17 NA 2.64 ± 1.39 NA 4.56 ± 1.59
Hoehn and Yahr score NA 2.00(1–3) NA 1.25(0–3) NA 2.25 (0–3)
Total MDS-UPDRS¢ 2.77 ± 4.05 51.59 ± 25.13 0.89 ± 1.85 39.57 ± 24.47 1.42 ± 2.87 39.90 ± 27.24  < 0.0001*  < 0.0001*  < 0.0001*
MDS-UPDRS I¢ 0.72 ± 0.98 2.50 ± 1.60 0.21 ± 0.42 1.81 ± 1.54 0.50 ± 0.80 2.27 ± 2.21  < 0.0001*  < 0.0001* 0.0062
MDS-UPDRS II¢ 0.32 ± 0.89 13.28 ± 6.56 0.10 ± 0.31 10.62 ± 6.59 0.50 ± 1.17 9.40 ± 7.49  < 0.0001*  < 0.0001*  < 0.0001*
MDS-UPDRS III¢ 1.72 ± 3.71 35.68 ± 18.29 0.58 ± 1.64 26.05 ± 16.69 0.42 ± 1.16 24.50 ± 19.06  < 0.0001*  < 0.0001*  < 0.0001*
Schwab and England scale¢ 99.54 ± 2.13 76.59 ± 22.55 100 ± 0 86 ± 11.42 100 ± 0 86.37 ± 12.25  < 0.0001*  < 0.0001*  < 0.0001*
Beck’s Depression Inventory¢ 5.54 ± 6.24 11.50 ± 8.00 2.42 ± 3.04 9.43 ± 7.41 5.83 ± 6.63 11.90 ± 10.90 0.003* 0.0013* 0.108
Comorbidities
 HBP 6.67% 33.3% 4.54% 45% 8.3% 40%
 T2D 0% 10% 4.54% 9% 8.3% 10%
 Hypercholesterolemia 0% 6.67% 0% 4.54% 0% 0%
 Dyslipidemia 0% 6.67% 4.54% 4.54% 0% 10%
  1. High blood pressure (HBP) Type 2 diabetes (T2D)
  2. ^data are reported as the percentage of subjects
  3. ¢data are reported as mean ± SD
  4. data are reported as median (range)
  5. *P ≤ 0.05 was considered as significant